Hamman-Rich syndrome pathophysiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(20 intermediate revisions by 2 users not shown)
Line 1: Line 1:


__NOTOC__
__NOTOC__
{{Hamman-Rich syndrome}}


{{CMG}}; {{AE}}  
{{CMG}}; {{AE}} {{CK}}


==Overview==
==Overview==
The exact pathogenesis of [disease name] is not fully understood.
[[Hamman-Rich syndrome|Acute interstitial pneumonitis]] shows the [[Histopathology|histopathologic appearance]] of diffuse [[Alveolus|alveolar]] damage. On [[gross examination]], lungs appear firm, heavy and have a dark red or beefy appearance and show irregular areas of [[Consolidation (medicine)|consolidation]] and [[fibrosis]]. On [[Microscopy|microscopic examination]], [[Hamman-Rich syndrome|acute interstitial pneumonitis]] shows  bilateral, temporal uniformity of the diffuse [[Alveolus|alveolar]] damage, hyaline membrane deposition and extensive [[Fibroblast|fibroblastic]] and [[Myofibroblast|myofibroblastic]] proliferation.
 
OR
 
It is thought that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
 
OR
 
[Pathogen name] is usually transmitted via the [transmission route] route to the human host.
 
OR
 
Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
 
OR
 
 
[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
 
OR
 
The progression to [disease name] usually involves the [molecular pathway].
 
OR
 
The pathophysiology of [disease/malignancy] depends on the histological subtype.


==Pathophysiology==
==Pathophysiology==


===Pathogenesis===
===Pathogenesis===
*The exact pathogenesis of [disease name] is not fully understood.
*The mechanism of initial [[injury]] to the pulmonary [[epithelium]] in [[Hamman-Rich syndrome|acute interstitial pneumonitis]] is not known.
OR
*Based on the findings of [[lung]] [[biopsy]], the uniformity and extent of the injury, it is assumed that a single insult triggers the pathologic process.
*It is understood that [disease name] is the result of / is mediated by / is produced by / is caused by either [hypothesis 1], [hypothesis 2], or [hypothesis 3].
*On microscopy, appearance of hyaline membrane remenats and organizing alveolar exudate may suggest that acute interstitial pnemonia  progresses from the exudative stage of diffuse alveolar damage.
*[Pathogen name] is usually transmitted via the [transmission route] route to the human host.
*Diffuse [[Alveolus|alveolar]] damage occurs in 3 stages.<ref name="pmid23028252">{{cite journal |vauthors=Nur Urer H, Ersoy G, Yılmazbayhan ED |title=Diffuse alveolar damage of the lungs in forensic autopsies: assessment of histopathological stages and causes of death |journal=ScientificWorldJournal |volume=2012 |issue= |pages=657316 |date=2012 |pmid=23028252 |pmc=3458269 |doi=10.1100/2012/657316 |url=}}</ref><ref name="pmid19647854">{{cite journal |vauthors=Kang D, Nakayama T, Togashi M, Yamamoto M, Takahashi M, Kunugi S, Ishizaki M, Fukuda Y |title=Two forms of diffuse alveolar damage in the lungs of patients with acute respiratory distress syndrome |journal=Hum. Pathol. |volume=40 |issue=11 |pages=1618–27 |date=November 2009 |pmid=19647854 |doi=10.1016/j.humpath.2009.04.019 |url=}}</ref>
*Following transmission/ingestion, the [pathogen] uses the [entry site] to invade the [cell name] cell.
**Acute, [[Exudate|exudative]]
*[Disease or malignancy name] arises from [cell name]s, which are [cell type] cells that are normally involved in [function of cells].
**Proliferative, organizing
*The progression to [disease name] usually involves the [molecular pathway].
**[[Fibrosis|Fibrotic]]
*The pathophysiology of [disease/malignancy] depends on the histological subtype.
*The rapid and abrupt onset of a widespread [[injury]] pattern may be suggested as an initiating factor involving [[Lung|pulmonary]] [[endothelium]]. This is followed by damage to [[Alveolus|alveolar]] [[epithelium]] and [[Programmed cell death|cell death]], that leads to release of mediating factors such as [[tumor necrosis factor alpha]], [[Interleukin|interleukins]] and monocyte chemoattractant factor.
*Followed by the influx of [[Neutrophil|neutrophils]] into the [[Alveolus|alveolar]] spaces and [[Alveolus|alveolar walls]] leads to further cellular damage, by the release of toxic [[Free radicals|oxygen free radicals]] and [[Protease|proteases]].  
*[[Neutrophil|Neutrophils]] and other [[Inflammation|inflammatory cells]] can contribute to the progression of the epithelial cell injury and airspace [[Exudate|exudation]].  
*The extent of [[Epithelium|epithelial]] [[injury]] and [[basement membrane]] damage may modulate the nature and extent of the subsequent [[Fibroblast|fibroblastic]] response in [[Hamman-Rich syndrome|acute interstitial pneumonitis]].
*Following the acute phase, a stage of organization occurs.
**The [[Hyaline|hyaline membranes]] are resorbed into the [[Alveolus|alveolar septa]] and overgrown by proliferating [[Pneumocytes|type II pneumocytes]].
*In fibrotic phase, proliferation of [[Fibroblast|fibroblasts]] and differentiation into [[Myofibroblast|myofibroblasts]] leads to the production of [[collagen]], causes widening of the [[Alveolus|alveolar]] septa, and organization of the [[Alveolus|alveolar]] [[exudate]].  
*Collapse of [[Alveolus|alveolar]] wall and apposition, associated with reepithelization of the fibrotic exudate within the [[Alveolus|alveolar]] space may contribute to the severity and extent of the [[Fibrosis|fibrotic process]].


==Genetics==
==Gross Pathology==
*[Disease name] is transmitted in [mode of genetic transmission] pattern.
*Genes involved in the pathogenesis of [disease name] include [gene1], [gene2], and [gene3].
*The development of [disease name] is the result of multiple genetic mutations.
 
==Associated Conditions==


==Gross Pathology==
*Patients with [[Hamman-Rich syndrome|acute interstitial pneumonitis]], [[Gross examination|gross appearance]] of [[Lung|lungs]] is identical to the [[Patient|patients]] with [[Acute respiratory distress syndrome|ARDS]].<ref name="pmid11019719">{{cite journal |vauthors=Tomashefski JF |title=Pulmonary pathology of acute respiratory distress syndrome |journal=Clin. Chest Med. |volume=21 |issue=3 |pages=435–66 |date=September 2000 |pmid=11019719 |doi= |url=}}</ref>
*On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
*The [[Gross examination|gross appearance]] of [[Lung|lungs]] correlates with the stage of the [[Acute respiratory distress syndrome|diffuse alveolar damage]].
**In the early phase, the [[Lung|lungs]] are firm, boggy, and have a  dark red or beefy appearance.
**In later phases, the [[Lung|lungs]] are extremely heavy due to [[edema]] and show irregular areas of dense [[Consolidation (medicine)|consolidation]] and [[fibrosis]].
**As the [[fibrosis]] progresses, cobblestoning of the [[Pleura|pleural surface]] may occur.
**Formation of peripheral [[Cyst|cysts]] and honeycombing may suggest the possibility of underlying chronic [[Fibrosis|fibrotic lung disease]].


==Microscopic Pathology==
==Microscopic Pathology==
*On microscopic [[Histopathology|histopathological analysis]], [[Hamman-Rich syndrome|Acute interstitial pneumonitis]] will show following features:<ref name="pmid23001802">{{cite journal |vauthors=Mukhopadhyay S, Parambil JG |title=Acute interstitial pneumonia (AIP): relationship to Hamman-Rich syndrome, diffuse alveolar damage (DAD), and acute respiratory distress syndrome (ARDS) |journal=Semin Respir Crit Care Med |volume=33 |issue=5 |pages=476–85 |date=October 2012 |pmid=23001802 |doi=10.1055/s-0032-1325158 |url=}}</ref>
*On microscopic [[Histopathology|histopathological analysis]], [[Hamman-Rich syndrome|Acute interstitial pneumonitis]] will show following features:<ref name="pmid23001802">{{cite journal |vauthors=Mukhopadhyay S, Parambil JG |title=Acute interstitial pneumonia (AIP): relationship to Hamman-Rich syndrome, diffuse alveolar damage (DAD), and acute respiratory distress syndrome (ARDS) |journal=Semin Respir Crit Care Med |volume=33 |issue=5 |pages=476–85 |date=October 2012 |pmid=23001802 |doi=10.1055/s-0032-1325158 |url=}}</ref><ref name="pmid12570127">{{cite journal |vauthors=Bonaccorsi A, Cancellieri A, Chilosi M, Trisolini R, Boaron M, Crimi N, Poletti V |title=Acute interstitial pneumonia: report of a series |journal=Eur. Respir. J. |volume=21 |issue=1 |pages=187–91 |date=January 2003 |pmid=12570127 |doi= |url=}}</ref>
**[[Diffuse alveolar damage]]
**[[Diffuse alveolar damage]]
**[[Hyaline]] membrane formation
**[[Hyaline]] membrane formation
**[[Interstitial lung disease|Interstitial fibrosis]]:
**[[Interstitial lung disease|Interstitial fibrosis]]:
***It is [[diffuse]], [[Uniform distribution|uniform]] temporally with extensive [[Fibroblast|fibroblastic]] and [[Myofibroblast|myofibroblastic]] proliferation and relatively less [[collagen]] deposition.
***It is [[diffuse]], bilateral, [[Uniform distribution|uniform]] temporally with extensive [[Fibroblast|fibroblastic]] and [[Myofibroblast|myofibroblastic]] proliferation and relatively less [[collagen]] deposition.
***The [[Uniform distribution|uniformity]] of the [[Fibroblast|fibroblastic]]/[[Myofibroblast|myofibroblastic]] proliferation and prominent activity distinguish AIP from the other types of idiopathic interstitial pneumonia.
***The [[Uniform distribution|uniformity]] of the [[Fibroblast|fibroblastic]]/[[Myofibroblast|myofibroblastic]] proliferation and prominent activity distinguish AIP from the other types of idiopathic interstitial pneumonia.
**[[Pneumocyte|Type II pneumocyte]] [[hyperplasia]] with cytologic [[atypia]] and [[Respiratory epithelium|bronchiolar]] [[Squamous epithelium|squamous]] [[metaplasia]] is present.
**[[Pneumocyte|Type II pneumocyte]] [[hyperplasia]] with cytologic [[atypia]] and [[Respiratory epithelium|bronchiolar]] [[Squamous epithelium|squamous]] [[metaplasia]] is present.
Line 67: Line 49:
**[[Biopsy|Biopsies]] taken in the later course of the [[disease]] show:
**[[Biopsy|Biopsies]] taken in the later course of the [[disease]] show:
***Enlarged and remodeled [[Alveolus|airspaces]] that resemble honeycomb change of UIP (usual interstitial fibrosis), but extensive [[Fibroblast|fibroblastic]]/ [[Myofibroblast|myofibroblastic]] proliferation and [[collagen]] deposition is still present within the walls of the [[Alveolus|alveoli]].
***Enlarged and remodeled [[Alveolus|airspaces]] that resemble honeycomb change of UIP (usual interstitial fibrosis), but extensive [[Fibroblast|fibroblastic]]/ [[Myofibroblast|myofibroblastic]] proliferation and [[collagen]] deposition is still present within the walls of the [[Alveolus|alveoli]].
 
[[File:Acute interstitial pneumonia (AIP) Idiopathic DAD.jpg|center|thumb|[[Idiopathic]] DAD<ref>By Yale Rosen [CC BY-SA 2.0 (<nowiki>https://creativecommons.org/licenses/by-sa/2.0</nowiki>)], via Wikimedia Commons</ref> in [[Hamman-Rich syndrome|Acute interstitial pneumonia]]]]
==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
Line 80: Line 62:
{{WS}}
{{WS}}


[[Category:Pulmonology]]
[[Category: Pulmonology]]

Latest revision as of 20:57, 23 March 2018


Hamman-Rich syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hamman-Rich syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hamman-Rich syndrome pathophysiology On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hamman-Rich syndrome pathophysiology

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hamman-Rich syndrome pathophysiology

CDC on Hamman-Rich syndrome pathophysiology

Hamman-Rich syndrome pathophysiology in the news

Blogs on Hamman-Rich syndrome pathophysiology

Directions to Hospitals Treating Hamman-Rich syndrome

Risk calculators and risk factors for Hamman-Rich syndrome pathophysiology

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chandrakala Yannam, MD [2]

Overview

Acute interstitial pneumonitis shows the histopathologic appearance of diffuse alveolar damage. On gross examination, lungs appear firm, heavy and have a dark red or beefy appearance and show irregular areas of consolidation and fibrosis. On microscopic examination, acute interstitial pneumonitis shows bilateral, temporal uniformity of the diffuse alveolar damage, hyaline membrane deposition and extensive fibroblastic and myofibroblastic proliferation.

Pathophysiology

Pathogenesis

Gross Pathology

Microscopic Pathology

Idiopathic DAD[6] in Acute interstitial pneumonia

References

  1. Nur Urer H, Ersoy G, Yılmazbayhan ED (2012). "Diffuse alveolar damage of the lungs in forensic autopsies: assessment of histopathological stages and causes of death". ScientificWorldJournal. 2012: 657316. doi:10.1100/2012/657316. PMC 3458269. PMID 23028252.
  2. Kang D, Nakayama T, Togashi M, Yamamoto M, Takahashi M, Kunugi S, Ishizaki M, Fukuda Y (November 2009). "Two forms of diffuse alveolar damage in the lungs of patients with acute respiratory distress syndrome". Hum. Pathol. 40 (11): 1618–27. doi:10.1016/j.humpath.2009.04.019. PMID 19647854.
  3. Tomashefski JF (September 2000). "Pulmonary pathology of acute respiratory distress syndrome". Clin. Chest Med. 21 (3): 435–66. PMID 11019719.
  4. Mukhopadhyay S, Parambil JG (October 2012). "Acute interstitial pneumonia (AIP): relationship to Hamman-Rich syndrome, diffuse alveolar damage (DAD), and acute respiratory distress syndrome (ARDS)". Semin Respir Crit Care Med. 33 (5): 476–85. doi:10.1055/s-0032-1325158. PMID 23001802.
  5. Bonaccorsi A, Cancellieri A, Chilosi M, Trisolini R, Boaron M, Crimi N, Poletti V (January 2003). "Acute interstitial pneumonia: report of a series". Eur. Respir. J. 21 (1): 187–91. PMID 12570127.
  6. By Yale Rosen [CC BY-SA 2.0 (https://creativecommons.org/licenses/by-sa/2.0)], via Wikimedia Commons

Template:WH Template:WS

References

Template:WH Template:WS